博茨瓦纳COVID-19大流行期间诱导化疗治疗局部晚期宫颈癌的疗效
这项前瞻性观察性研究比较了2019至2022年接受诱导化疗联合放疗或放化疗的局部晚期宫颈癌患者(n=67)与2014至2019年接受放化疗的历史对照(n=169)。诱导化疗联合放疗或放化疗组2年总生存率为80.2%,历史放化疗组为77.5%,两组无差异;多变量分析显示接受≥3个周期诱导化疗与总生存改善相关。作者认为当放疗延迟时诱导化疗可能是可行的治疗路径。
要点
- 诱导化疗联合放疗或放化疗组2年总生存率80.2%,历史放化疗组77.5%,两组无差异。
- 多变量分析显示接受≥3个周期诱导化疗与总生存改善相关。
- 在预设诱导化疗联合放疗或放化疗的患者(n=91)中,2年总生存率66.8%,与历史放化疗对照无差异。
核心结论
- 接受诱导化疗联合放疗或放化疗的患者生存与历史放化疗对照无差异,且与≥3个周期诱导化疗相关,提示当放疗延迟时诱导化疗可能是可行的治疗路径。
研究设计与样本
- 前瞻性观察性研究,比较2019至2022年接受诱导化疗联合放疗或放化疗的局部晚期宫颈癌患者(n=67)与2014至2019年接受放化疗的历史对照(n=169)。
- 诱导化疗联合放疗或放化疗方案为紫杉醇175 mg/m2联合卡铂(曲线下面积5-6)每三周一次共四个周期,随后外照射放疗和高剂量率近距离放疗,联合或不联合每周同步顺铂。
主要发现
- 中位随访28.9个月(95%CI 27.4-32.7个月)。
- 诱导化疗联合放疗或放化疗组2年总生存率80.2%(95%CI 69.8-92.1%),历史放化疗组77.5%(95%CI 71.3-84.1%),两组无差异。
- 多变量分析显示接受≥3个周期诱导化疗与总生存改善相关。
- 在预设诱导化疗联合放疗或放化疗的患者(n=91)中,2年总生存率66.8%(95%CI 56.9-78.3%),与历史放化疗对照无差异。
- 多变量分析显示接受预设的诱导化疗联合放疗或放化疗与总生存改善相关。
临床怎么用
- 作者认为当放疗延迟时诱导化疗可能是可行的治疗路径。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Standard chemoradiation (CRT) treatment for cervical cancer was disrupted in Botswana during the COVID-19 pandemic. Patients were prescribed induction chemotherapy (IC) to bridge delays to radiotherapy (RT) or CRT (IC + RT/CRT). METHODS: This prospective observational study compared outcomes of locally advanced cervical cancer patients who received IC + RT/CRT (n = 67) between 2019 and 2022 to historical controls who received CRT (n = 169) between 2014 and 2019. IC + RT/CRT consisted of four cycles of paclitaxel 175 mg/m2 and carboplatin (area under the curve 5-6) prescribed once every three weeks followed by external beam RT and high-dose-rate brachytherapy with or without weekly concurrent cisplatin. Two-year overall survival (OS) was estimated using the Kaplan-Meier method; univariable and multivariable analyses (MVA) were conducted using Cox proportional hazards regression. RESULTS: Median follow-up was 28.9 months (95 % CI 27.4-32.7 months). Two-year OS of the IC + RT/CRT cohort (80.2 % [95 % CI: 69.8-92.1 %]) did not differ from the historical CRT cohort (77.5 % [95 % CI 71.3-84.1 %]). Improved OS was associated with receiving ≥3 cycles of IC on MVA. Secondary analysis among those prescribed IC + RT/CRT (n = 91) demonstrated no difference in 2-year OS (66.8 % [95 % CI: 56.9-78.3 %]) compared to CRT historical controls. Receipt of the prescribed IC + RT/CRT was associated with increased OS on MVA. CONCLUSIONS: Survival of patients who received IC + RT/CRT did not differ from historical CRT controls and was associated with ≥3 cycles of IC, suggesting that IC may be a feasible treatment pathway when RT is delayed.
引用
- MacDuffie E, Kernell C, George J, et al. Efficacy of induction chemotherapy during the COVID-19 pandemic for treatment of locally advanced cervical cancer in Botswana. Gynecol Oncol. 2025. PMID: 39983352. doi:10.1016/j.ygyno.2025.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。